Efficacy and Safety of Blinatumomab in Adult Patients with B-Cell Acute Lymphoblastic Leukemia
10.19746/j.cnki.issn1009-2137.2025.06.004
- VernacularTitle:贝林妥欧单抗治疗成人急性B淋巴细胞白血病的疗效及安全性分析
- Author:
Ya-Lei HU
1
;
Yong-Feng SU
;
Yang LI
;
Xuan ZHENG
;
An WANG
;
Yi-Zhi WANG
;
Lei XU
;
Chun-Ji GAO
;
Liang-Ding HU
;
Dai-Hong LIU
;
Xiao-Ning GAO
Author Information
1. 解放军总医院第五医学中心血液病医学部,北京 100071;解放军医学院,北京 100853;解放军总医院海南医院血液科,海南三亚 572000
- Publication Type:Journal Article
- Keywords:
blinatumomab;
B-cell acute lymphoblastic leukemia;
relapsed/refractory;
measurable residual disease
- From:
Journal of Experimental Hematology
2025;33(6):1571-1576
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of blinatumomab in adult patients with relapsed/refractory(R/R)or measurable residual disease(MRD)positive B-cell acute lymphoblastic leukemia(B-ALL)in the real world.Methods:The clinical data of 30 B-ALL patients received at least 1 course of blinatumomab therapy in the Chinese PLA General Hospital from January 1st,2021 to December 31st,2023 were retrospectively analyzed,including pre-treatment baseline clinical feature,post-treatment complete response(CR),CR with partial hematologic recovery(CRh),CR with incomplete hematologic recovery(CRi),complete MRD response rate,MRD response rate(MRD＜10-4),overall survival(OS),and disease-free survival(DFS),as well as drug-related adverse reactions.Results:Among 5 patients who were not assessed 4 were MRD negative and 1 did not receive bone marrow biopsy.In the R/R B-ALL group(13 cases),11 patients achieved CR/CRh/CRi and 10 patients achieved complete MRD response.In MRD+group(12 cases),9 patients achieved overall MRD response and 7 patients achieved complete MRD response.The median follow-up time was 8.4(95％CI:6.3-10.4)months.The median OS was 15.5(95％CI:0.7-30.3)months in the R/R group,while not reached in the MRD+group.The median DFS of the two groups were not reached.Drug-related adverse reactions occurred in 22 patients,and pyrexia was the most common(13 cases).Grade ≥3 adverse reactions occurred in 15 patients,and neutropenia was the most common(9 cases).Cytokine release syndrome occurred in 6 patients,including 5 cases with grade 1 and 1 case with grade 3.No patients interrupted therapy or died due to drug-related adverse reactions.Conclusion:Blinatumomab is effective in the treatment of R/R or continuous MRD+B-ALL with acceptable adverse reactions.
